SB 26-140

Senate Bill 26-140, which has been signed into law, exempts certain prescription drugs from affordability reviews conducted by Colorado’s Prescription Drug Affordability Review Board. Specifically, it protects drugs designated for rare diseases or conditions and biological products derived from human blood or plasma from being reviewed for cost-effectiveness and price limits. This means that the board won’t be able to set upper payment limits on these specific medications, potentially affecting patients who rely on them for treatment of rare diseases or certain medical conditions.

Official Summary

The bill states that the Colorado prescription drug affordability review board has no authority to perform an affordability review of, or to establish an upper payment limit for, a prescription drug that is:Designated as a drug for a rare disease or condition by the food and drug administration (FDA) of the federal department of health and human services; orA licensed biological product that is derived from human whole blood or plasma as indicated on product labeling approved by the FDA.(Note: This summary applies to the reengrossed version of this bill as introduced in the second house.)

Topics

Votes